Symbol
| EPO
| contributors: mct - updated : 27-04-2016
|
HGNC name
| erythropoietin
|
HGNC id
| 3415
|
Susceptibility
|
to proliferative diabetic retinopathy (PDR) and end stage renal disease (ESRD) |
Variant & Polymorphism
other
| loss of function leading to reduced hippocampal neurogenesis |
|
polymorphisms increasing the risk of proliferative diabetic retinopathy (PDR) and end stage renal disease (ESRD) |
|
|
Candidate gene
| EPO is increased in the vitreous fluid from ischemic retinal diseases such as proliferative diabetic retinopathy |
|
EPO is expressed in the human retina, and it is upregulated in diabetic patients even without retinopathy |
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cardiovascular | aquired | | |
EPO/EPOR is a novel therapeutic target in cardiovascular disease | diabete | | | |
promotion of EPO signaling in beta cells may be a novel therapeutic strategy for diabetes prevention and treatment | neurology | neurodegenerative | | |
EPO administration can be a new promising therapeutic approach in amyotrophic lateral sclerosis | neurology | neurodegenerative | alzheimer | |
may be useful for the treatment of AD |
| | |
| deletion of the Epo gene in mice leads to embryonic lethality at days 13 to 15, coincident with the establishment of definitive (adult-type) erythropoiesis and underscoring the absolute necessity of Epo function |